Business Context and Reporting Period
Company: USANA Health Sciences, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 30, 2002
Business Overview: USANA develops and manufactures nutritional, personal care, and weight management products distributed via a network marketing system. Primary product lines include USANA Nutritionals (67% of sales), LEAN Lifelong (10%), and Sensé (12%). Operations span the U.S., Canada, Australia, New Zealand, Hong Kong, and Japan.
Key Financial Metrics
| Metric | Q1 2002 | Q1 2001 |
|---|---|---|
| Net Sales | $28.6 million | $27.6 million |
| Gross Profit | $20.9 million (73.1% margin) | $19.6 million (71.1% margin) |
| Net Earnings | $1.1 million | $0.5 million |
| Earnings Per Share (Diluted) | $0.12 | $0.05 |
| Cash from Operations | $3.2 million | $5.3 million |
| Cash and Equivalents (End of Period) | $3.3 million | $2.5 million |
| Total Debt (Current + Long-term) | $10.1 million | $10.1 million |
| Working Capital | $1.2 million | $0.4 million |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 3.7% ($1.0 million) driven by the launch of the Japan market and strong associate enrollments in mature markets. Growth was partially offset by weaker foreign currencies and lower unit volume in Australia-New Zealand despite a price increase.
- Profitability: Net earnings surged 137.2% to $1.1 million. Gross margin improved to 73.1% due to procurement efficiencies, the Australia-New Zealand price increase, and higher-margin sales in Japan.
- Expense Management: Associate incentives decreased as a percentage of sales (37.5% vs. 38.0%) due to the new Japan market structure and higher sales of non-commissionable sales aids. Selling, general, and administrative (SG&A) expenses rose to 28.1% of sales, attributed to costs related to a terminated asset sale transaction and Japan market support.
- Interest and FX: Interest expense dropped $161,000 due to lower rates and reduced debt. Foreign currency exchange losses decreased by $385,000 compared to the prior year.
Outlook, Risks, and Unusual Items
- Terminated Transaction: On April 9, 2002, the Company terminated an agreement to sell operating assets to a company controlled by its founder, Myron W. Wentz, Ph.D. Costs related to this proposed transaction impacted Q1 SG&A expenses.
- Liquidity and Debt: The Company maintains a $22.5 million credit facility ($10M term loan, $12.5M line of credit). As of March 30, 2002, $7.5 million was outstanding on the term loan and $2.6 million on the line of credit. Credit covenants were amended in April 2002 to ensure compliance.
- Forward-Looking Risks: Key risks include reliance on the network marketing model, high associate turnover, foreign currency fluctuations (44.3% of sales are international), and regulatory scrutiny of network marketing practices. The Company has no hedging instruments in place for foreign currency exposure.
- Guidance: Management expects associate incentives as a percentage of sales to trend toward historical levels in coming quarters. No specific financial guidance for the full year was provided in this filing.
Investor Verification Checklist
- Japan Market Performance: Verify the sustainability of the Japan segment's contribution to revenue and margins, as it is a new operation.
- Associate Retention: Monitor associate turnover rates and enrollment trends, as the business model relies heavily on the network marketing system.
- Currency Exposure: Assess the impact of a strengthening U.S. dollar on international sales, given the lack of hedging instruments.
- Debt Covenants: Confirm ongoing compliance with the amended credit facility covenants, specifically the fixed charge coverage ratio.
- Asset Sale Termination: Review the financial impact of the terminated asset sale and any lingering legal or operational costs.